Seeking Alpha

The FDA has asked for more information from Regeneron (REGN) about the use of its...

The FDA has asked for more information from Regeneron (REGN) about the use of its autoinflammatory drug Arcalyst to treat joint pain caused by gout medicines. The FDA has concerns about Arcalyst's links to cancer. The drug is already approved to treat a rare genetic autoinflammatory disease; extending its use for gout could have added up to $200M a year in sales.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs